Each film coated tablet contains: Loratadine 10 mg.
Loratadine is a long acting tricyclic antihistamine with selective H1 receptor antagonist activity, Loratadine doesn't appear sedative effects or anti-cholinergic.
For the treatment of symptoms caused allergic rhinitis i.e. cold, sneezing, itching. Treatening such as skin allergic rhinitis and chronic idiopathic urticaria.
Adult, elderly and children above 12 years: 1 tablet (10 mg) once daily.
Children 2-12 years: Body weight > 30 kg: 1 tablet (10 mg) once daily.
Body weight ≤ 30 kg: 1/2 tablet (5 mg) once daily.
Safety and efficacy use in children under 2 years is not establish.
In adults, somnolence, tachycardia, headache, and extrapyramidal signs, and palpitations in children have been reported with overdoses of greater than 10 mg of Loratadine. In the event of overdosage, general symptomatic and supportive measure should be instituted promptly to patients:
Patients should be induced to vomit, even if emesis has occurred spontaneously.
Pharmacologically- induced vomiting by administration of ipecac syrup, however vomiting should not be induced in patients with impaired consciousness. If emesis does not occur within 15minutes, the dose of ipecac should be repeated. Following emesis adsorption of any drug remaining in the stomach may be attempted by the administration of activated active carbon with water. If vomiting is unsuccessful, or contraindicated, gastric lavage should be performed with physiologic saline solution, particularly in children. In adults, tap water can be used.
Loratadine is not removed by hemodialysis. After emergency treatment, the patient should continue to be under medical supervision.
Patients who have hypersensitivity or idiosyncrasy to Loratadine.
Patients with renal impairment should be given a lower initial dose, because it may decrease clearence potential of Loratadine, the recommended initial dose is 5 mg once a day or 10 mg every two days.
Safety and efficacy of Loratadine in children under 2 years old have not been established.
Do not use Loratadine during pregnancy unless the potential benefit justifies the potential risk to fetus.
Should not be recommended to lactating women because it will be excreted to the breast milk.
Sedative effects of Loratadine have no significant effect appear in patients who received 10 mg Loratadine once a day.
Adverse reactions tiredness, headache, somnolence, dry mouth, gastrointestinal disturbance, nausea, and skin allergic reactions i.e. rash.
Alopecia, anaphylaxis, abnormal hepatic function, and supraventicular tachyarrythmias have been rarely reported.
When administered concomitantly with alcohol, Loratadine has no potentiating effect as measured by psychomotor performance studies.
Increases plasma concentrations of Loratadine have been reported after concomitant use with Erithromycin, Ketoconazole, & Cimetidine in controlled clinical studies, but without clinically significant effect including electro-cardiographic parameters.
Caution should be exercised if Loratadine is coadministered with hepatic metabolism inhibitor medicines.
Administration of antihistamines should be discontinued about ± 48 hours prior to skin testing procedures, since these medicines may prevent or diminish otherwise positive reactions to dermal reactivity indicators.
R06AX13 - loratadine ; Belongs to the class of other antihistamines for systemic use.
Loracor tab 10 mg
5 × 10's
Sign Out
